Biocon Limited reported consolidated operating revenue of Rs 4,389 crore for the second quarter of FY27, up 2% year-on-year (YoY), as growth in its biopharmaceutical business and services revenue helped offset a mixed performance across segments.
The company's total income stood at Rs 4,423 crore, while consolidated EBITDA came in at Rs 865 crore. Net profit was Rs 41 crore during the quarter ended September 30, 2026.
Biopharma revenue, the company's key growth engine, rose 5% YoY to Rs 3,583 crore. Within the segment, biosimilars revenue increased 3% to Rs 2,809 crore, while generics revenue climbed 10% to Rs 774 crore.
Services revenue recorded a stronger performance, rising 13% quarter-on-quarter to Rs 833 crore.
Biocon's interest costs continued to decline, falling 12% YoY to Rs 240 crore, reflecting the impact of measures taken to strengthen its balance sheet. Net profit before exceptional items stood at Rs 44 crore.
A key highlight of the quarter was Biocon's landmark 10-year biosimilar Pertuzumab PDP partnership in Brazil, valued at approximately USD 400 million. The deal adds a significant long-term growth opportunity to the company's biosimilars portfolio.
The company also reported progress in its global biosimilar expansion strategy, including regulatory and manufacturing milestones.
Biocon's Pertuzumab became the first monoclonal antibody biosimilar recommended under the European Medicines Agency's (EMA) new tailored clinical development pathway, marking a significant development for biosimilar innovation.
The company also operationalised its second Insulin Glargine fill-finish line in Malaysia, with commercial supplies already underway.
Biocon Executive Chairperson Kiran Mazumdar-Shaw said the company continued to achieve industry firsts in biosimilars, while strengthening its global manufacturing capabilities.
“Biocon continued to achieve industry firsts in biosimilars, with our Pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway. This represents an important milestone for biosimilar innovation and patient access.
"The operationalization of our second Insulin Glargine fill-finish line in Malaysia, with commercial supplies already underway, further reaffirms our global manufacturing excellence. Together with our continued investments in technology and innovation, these milestones reflect the progress of our strategic transformation and reinforce our confidence in Biocon’s long-term growth trajectory.”
Shreehas Tambe, CEO and Managing Director of Biocon, said the company had made significant progress on its strategic priorities and was laying the groundwork for a stronger second half of FY27.
He highlighted the global settlement with Genentech for Pebrilzo (biosimilar Pertuzumab), which secured the earliest licensed launch dates across Europe, the UK, the US and emerging markets.
“This quarter we continued to make significant progress on our strategic priorities, laying the foundation for a stronger second half of FY27. Our global settlement with Genentech for Pebrilzo (biosimilar Pertuzumab) secured the earliest licensed launch dates across Europe, UK, the U.S. and emerging markets providing greater visibility to a significant future growth driver.
"We also secured a landmark 10-year Pertuzumab PDP partnership in Brazil valued at ~USD 400 million, underscoring our ability to win and execute large-scale biologics deals.
"Together with the upcoming European launch of Pertuzumab, expanded insulin manufacturing capacity in Malaysia to support growing U.S. demand, and the strong early momentum of Yesafili and Yesintek in the U.S., we are well positioned for growth in the second half of FY27.”
With the anticipated European launch of Pertuzumab, expanded insulin manufacturing capacity and growing traction for Yesafili™ and Yesintek® in the US market, Biocon is banking on its biosimilars pipeline and global expansion strategy to drive momentum in the coming quarters.
